Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Prospectus
Announcements
2020.11.10
FIRST PATIENT DOSED IN THE PHASE 3 CLINICAL TRIAL OF OREGOVOMAB
2020.11.04
"INHIXA" OBTAINS APPROVAL FROM SFDA
2020.11.02
Monthly Return of Equity Issuer on Movements in Securities for the month ended 3...
2020.10.29
2020 THIRD QUARTERLY REPORT
2020.10.26
PASSING OF CONSISTENCY EVALUATION FOR THE GENERIC DRUG OF ALL STRENGTHS OF "ENOX...
2020.10.16
DATE OF BOARD MEETING
2020.10.06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 3...
2020.09.24
Notification Letter and Request Form to Non-Registered Shareholder
2020.09.24
2020 Interim Report
2020.09.21
"ENOXAPARIN SODIUM INJECTION" OBTAINS APPROVAL FROM FDA
第一页
上一页
15
16
17
18
19
下一页
最后一页
